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Abstract
Careful characterization and standardization of the composition of plant-derived food supplements is essential
to establish a cause-effect relationship between the intake of that product and its health effect. In this review
we follow a specific grape seed extract containing monomeric and oligomeric flavan-3-ols from its creation
by Jack Masquelier in 1947 towards a botanical remedy and nutraceutical with proven health benefits. The
preparation’s research history parallels the advancing insights in the fields of molecular biology, medicine,
plant and nutritional sciences during the last 70 years. Analysis of the extract’s flavanol composition emerged
from unspecific colorimetric assays to precise high performance liquid chromatography - mass spectrometry
and proton nuclear magnetic resonance fingerprinting techniques. The early recognition of the preparation’s
auspicious effects on the permeability of vascular capillaries directed research to unravel the underlying
cellular and molecular mechanisms. Recent clinical data revealed a multitude of favorable alterations in the
vasculature upon an 8 weeks supplementation which summed up in a health benefit of the extract in
healthy humans. Changes in gene expression of inflammatory pathways in the volunteers’ leukocytes were
suggested to be involved in this benefit. The historically grown scientific evidence for the preparation’s health
effects paves the way to further elucidate its metabolic fate and molecular action in humans.
Keywords: Flavanols, Proanthocyanidins, Grape seed, Masquelier, Cardiovascular, Health, Inflammation,
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Introduction
In scientifically evaluating the health benefit of a
food-derived product, three major rules have to be
followed: 1) The product for which a health claim is made
should be well characterized; 2) the (claimed) effect should
be well defined and of physiological benefit; 3) a cause-and-
effect relationship between the intake of the food product
and the claimed effect on human health is substantiated by
human (observational and intervention) studies. In this
review we will follow a specific botanical preparation, i.e. a
mixture of monomeric and oligomeric flavan-3-ols from
the seeds of grapes, on its travel from its creation in 1947
towards a botanical remedy and nutraceutical with proven
health benefits.
The authentic mixture of monomeric and oligo-
meric flavan-3-ols extracted from the seeds of grapes
(Vitis vinifera L.) is commercially available as the
herbal remedy Endotélon® and as Masquelier’s®
Original OPCs (Anthogenol®) in various food supple-
ments. This plant extract forms an interesting
example of how product-specific research followed
and contributed to the scientific evolution of botan-
ical, biochemical and physiological insights during the
post-WWII period. In this time, grape seed extracts
constantly remained at the forefront of successive in-
novations in scientific investigation [1]. Applications
have been found in the treatment of chemo- and
radiotherapy-induced toxicity [2], in chemoprevention
[3–5], in cardiovascular diseases [6] and neurodegen-
erative diseases [7, 8], in oral health [9] or as cosme-
ceutical [10]. In the early development some focus* Correspondence: a.weseler@maastrichtuniversity.nl
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was given to the effect of grape seed extracts as phle-
botonics for venous insufficiency [11].
Research on the bioactive components of grape
seeds extracts, i.e. in flavonoids, started in the begin-
ning of the 20th century, when nutritional scientists
were dedicated to the isolation and identification of
compounds we came to define as “vitamins.” The
Hungarian scientist Albert Szent-Györgyi isolated vi-
tamins C and P from citrus fruits. In contrast to
vitamin C, the chemical characterization of vitamin
P appeared to be difficult. As a result, it was not
possible to attribute the vitamin P effect to a specific
compound or preparation. Moreover, the notion of
such a vitamin was abandoned since no deficiency
disease could be linked to Szent-Györgyi’s citrus
extract. However, the biological effect of “vitamin P”,
i.e. its influence on vascular permeability was estab-
lished as well as its enforcing influence on the anti-
scurvy effect of vitamin C. Efforts to identify this
putative vitamin P were directed to yellow colored
plant pigments, the flavonoids (flavus (Latin) means
yellow).
In 1947 the French researcher Jack Masquelier ex-
tracted during his work for his PhD thesis a colorless
fraction from the red-brown skin of peanuts. He found
this fraction to be responsible for the vitamin P effect
in animals and proposed its major components as oligo-
mers of flavan-3-ol units (i.e. (+)-catechin or (-)-epicate-
chin; Fig. 1). Nowadays, these polyphenolic compounds
are commonly classified as monomeric and oligomeric
flavan-3-ols. Condensed flavanols (oligomers and poly-
mers) are also designated as proanthocyanidins. Oligo-
mers of proanthocyanidins are well-known by the
abbreviation “OPCs.” As the name suggests, proantho-
cyanidins are the precursors (pro) of anthocyani(di)ns
(anthos (ancient Greek) means flower and kyanos (an-
cient Greek) means blue), which are water-soluble pig-
ments being responsible for the blue, violet or red color
of many flowers and fruits. In plants, anthocyanins are
usually present as glycosides, i.e. bound to one or several
Fig. 1 Molecular structure of monomeric and oligomeric flavan-3-ols
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sugar moieties. Their color depends on the pH of their
environment changing from red/pinkish at acidic condi-
tions to blue—purple at neutral conditions and yellowish
at alkaline conditions.
In any case, the scientific journey in the field of extracts
consisting of monomeric and oligomeric flavanols begins
in the early attempt to classify these compounds as a vita-
min amidst all other vitamins that were discovered in
those days. As nutrients that are essential to prevent
symptoms of deficiency, vitamins were realized to ensure
and procure health. In this context, the first discovered
health effects of Masquelier’s flavanol-preparations fitted
well in the, at that time, new WHO definition of health as
“a state of complete physical, mental and social well-being
and not merely the absence of disease or infirmity” [12].
Besides developing synthetic routes [13] and improving
methods for the extraction of monomeric and oligomeric
flavanols from different plant sources, Jack Masquelier also
directed much of his and his colleagues’ efforts to elucidate
the biological activities of the extracts produced. In recent
years, quite some scientific data have been generated that
provide insights in the presumed effects of all sorts of more
or less well defined grape seed extracts on human health.
However, in contrast to drugs, which are mostly single
chemical compounds, the evaluation of the biological
effects of phytochemicals produced by extraction is challen-
ging. The fact that most plant extracts contain a wide
variety of individual chemical entities bedevils the establish-
ment of a relationship between an effect in a biological test
system and an individual, chemically-defined molecule
which is part of the extract. For this reason, the extract
as a whole has to be regarded as the biologically active
entity. Therefore, to maintain and assure physiological
consistency, it is essential to have a well-characterized and
standardized plant extract available, of which each batch
possesses the qualitative and quantitative composition of
the researched preparation. Monomeric and oligomeric
flavanols are heterogeneous phytochemicals that differ in
their polymerization degree, stereochemistry and linkage of
the monomeric units. As described later in detail, particular
(parts of) plants are rich in these flavanols such as pine bark
and grape seeds. A recently performed literature search in
PubMed (http://www.ncbi.nlm.nih.gov/pubmed; search
performed on 8 July 2016) using the search terms “grape”
and “seed” and “extract” yielded 995 hits. However, a clear
picture on the bioactivity and health effects of the category
of extracts loosely defined as “grape seed-derived flavanols”
can hardly be obtained, since data on the qualitative and
quantitative composition of the investigated extracts are
either missing, imprecise or incomparable. Therefore, in this
review, we decided to focus on Masquelier’s grape seed-
derived monomeric and oligomeric flavanols extract
(Masquelier’s Original OPCs®), since it has a well-defined,
consistent composition (vide infra) and an over decades
established pool of in vitro, in vivo and clinical data unravel-
ling health benefits of monomeric and oligomeric flavanols
(Fig. 2).
Many plant products originate from traditional use.
Historical findings and concepts that come with it are a
valuable source to get insides into the origin and poten-
tial health effects of these products. The data on Masque-
lier’s flavanol preparation suggest a vitamin-like action
on capillary function, which can be associated with the
monomeric and oligomeric flavanols present in this ex-
tract. A closer look at the biosynthetic origin of flavanols
in plants may help to better understand their chemical
nature and biological activity.
Flavanol biosynthesis in plants
Monomeric flavan-3-ols like (-)-epicatechin and (+)-cat-
echin are enzymatically synthesized by plants via a com-
bination of the shikimate and the acetate pathway [14].
The first step towards the synthesis of shikimic acid con-
sists of the condensation of phosphoenolpyruvate (PEP;
produced in glycolysis) and D-erythrose-4-phosphate
(produced in pentose phosphate cycle) to 3-deoxy-D-
arabinose-heptulosonic acid-7-phosphate (DAHP; Fig. 3a).
Intramolecular aldol-type condensation and NADH-
mediated redox reactions result in dephosphorylation and
cyclization to 3-dehydroquinic acid. Dehydration and
reduction of the latter give shikimic acid which is eventu-
ally converted to chorismic acid. Chorismic acid serves as
the precursor of the amino acids L-tyrosine and L-
phenylalanine. From both amino acids 4-hydroxycinnamic
acid (p-coumaric acid) is generated. Upon esterification
with coenzyme A 4-hydroxycinnamoyl-CoA is extended
by 3 malonyl-CoA units which are derived from the acet-
ate pathway (Fig. 3b). This reaction is catalyzed by the
enzyme chalcone synthase and leads via a polyketide inter-
mediate to naringenin-chalcone. A Michael-type nucleo-
philic attack of one of the phenolic OH-groups on the
α,β-unsaturated ketone results in the C-ring formation
and yields the flavanone naringenin (Fig. 3b). Naringenin
is the basic molecule from which all different flavonoid
subclasses are synthesized including flavan-3-ols. Hydrox-
ylation of naringenin by flavanone-3-hydroxylase (F3H)
and subsequent NADPH-dependent reduction by
dihydroflavanol-4-reductase (DFR) produces leucoantho-
cyanidins such as leucocyanidin. Leucoanthocyanidins can
be converted by leucoanthocyanidin reductase (LAR) to
2,3-trans-(+)-flavan-3-ols like (+)-catechin. Moreover, they
are oxidized by anthocyanidin synthase (ANS) to antho-
cyanidins which are reduced by anthocyanidin reductase
(ANR) into 2,3-cis(-)-flavan-3-ols like (-)-epicatechin
(Fig. 3b). The formation of 2,3-cis configured flavan-3-ols
is remarkable because all chiral intermediates in the fla-
vonoid biosynthesis pathway have a 2,3-trans configur-
ation. Since the majority of proanthocyanidins are
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condensed products of (-)-epicatechin and (+)-catechin, it
is obvious that the stereochemistry of the oligomers varies
depending on the number and position of the (-)-epicate-
chin and (+)-catechin units. It is an ongoing debate if the
polymerization of (-)-epicatechin and (+)-catechin units is
facilitated by enzymes or occurs non-enzymatically [15].
Efforts to identify an enzyme that controls the condensa-
tion of the precursor units to proanthocyanidins have yet
not been successful [16]. Polyphenol oxidase (PPO) has
been suggested as a possible candidate (Fig. 3c) since it
can catalyze the conversion of (-)-epicatechin and (+)-cat-
echin to their corresponding quinone methides [17]. How-
ever, the physiological relevance of this mechanism
remains doubtful because oligomeric flavanols are formed
in the vacuole while PPO is usually located on plastids or
chloroplasts [18]. An oxidase with similar catalytic activity
in the vacuole has not been found until now.
Under acidic conditions in vitro proanthocyanidins
could be synthesized from leucoanthocyanidins which
condensate with (-)-epicatechin or (+)-catechin via the
formation of a quinone methide and carbocation (flavy-
lium cation) at the C4 position [19] (Fig. 3c). The elec-
trophilic C4 of the leucoanthocyanidin (flavan-3,4-diol,
i.e. the extension (upper) unit) reacts with the nucleo-
philic C6 or C8 position of the flavan-3-ol (i.e. the
starter/terminal (lower) unit). However, the existence of
an acidic compartment in plant cells was controversial
until recent findings in Arabidopsis thaliana showed
that gene disruption of the plasma membrane H
+-ATPase AHA10 caused a substantial loss of proantho-
cyanidin accumulation in the seed coat endothelium
[20]. Assuming that AHA10 or other plant H+-ATPases
contribute to the acidification of cytoplasmic or vacuolar
compartments, non-enzymatic condensation reactions in
an acidic environment may occur in plants (Fig. 3c).
Despite many unresolved questions on the precise mo-
lecular processes leading to the proanthocyanidins for-
mation in plants, a wealth of different structures has
been identified so far. Based on their hydroxylation pat-
tern oligomeric flavan-3-ols are classified in subgroups
like procyanidins that have a 3’,4’-dihydroxylation pattern
in the B-ring ((+)-catechin and (-)-epicatechin extension
units), propelargonidins with 4’-hydroxylation pattern in
the B-ring ((+)-afzelechin and (-)-epiafzelechin extension
units) and prodelphinidins with 3’,4’,5’-trihydroxylation
pattern ((+)-gallocatechin and (-)-epigallocatechin exten-
sion units). The hydroxylation pattern of the A and C-
ring is identical in these 3 subgroups and comprises
OH-groups at C3, C5 and C7. However, more
proanthocyanidin-subgroups have been isolated from
plants or chemically synthesized that differ in their posi-
tions of OH-groups in the A and C ring [16]. In accord-
ance to the interflavan linkage procyanidins are
classified in A- and B-type. Oligomers (and polymers) of
the B-type are linked via 1 bond which is usually located
between C4 of the extension (upper) unit and the C6 or
Fig. 2 Timeline of achievements in the field of molecular biology, medicine and nutritional science during the last decade which are paralleled
by achievements in the development and investigation of a grape seed extract by the French scientist Jack Masquelier. Today this preparation of
monomeric and oligomeric flavan-3-ols is commercially available in the herbal remedy Endotélon® and as Masquelier’s® Original OPCs in
nutraceuticals and food supplements
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C8 of the starting/terminating (lower) unit (e.g. procya-
nidin B5, Fig. 1). In addition to this C-C-linkage, A-type
proanthocyanidins possess an ether bond between the
C2 of the upper flavan-3-ol unit and the O at the C5 or
C7 position of the lower unit (e.g. procyanidin A1, Fig. 1).
In both types, the stereochemistry of the linking bond(s)
between two and more flavan-3-ol units can be either α
(denoted as hashed wedge in the molecular structural
formula) or β (denoted as solid wedge). In order to cope
with the increasing numbers of individual proanthocyani-
dins structurally elucidated in plants, a novel nomenclature
has been introduced to unequivocally designate the com-
plex molecular structures with higher polymerization de-
gree [21]. The building units of the oligomers are named
according to their names as monomeric flavan-3-ols fram-
ing parenthesis which specify the C-position and direction
of the interflavan linkage indicated as an arrow. For ex-
ample, the dimer procyanidin B1 is designated as epicate-
chin-(4β→ 8)-catechin, the dimer procyanidin A1 (Fig. 1)
is given as epicatechin-(4β→ 8, 2β→ 7)-catechin and the




Fig. 3 a-c Biosynthesis of monomeric and oligomeric flavan-3-ols in plants (panel a-c). a Shikimate pathway starting from phosphoenol
pyruvate (PEP) and D-erythrose-4-phosphate (D-erythrose-4-P) leading to the formation of 4-hydroxycinnamoyl alcohol, DHAP = 3-deoxy-D-
arabinose-heptulosonic acid-7-phosphate, NAD = nicotine-adenine dinucleotide, NADPH = reduced nicotine-adenine dinucleotide phosphate;
b Formation of monomeric flavan-3-ols (+)-catechin and (-)-epicatechin from 4-hydroxycinnamoyl-CoA and 3 molecules of malonyl-CoA,
F3H = flavanone-3-hydroxylase, F3’H = flavanone-3’-hydroxylase, DFR = dihydroflavanol-4-reductase, ANS = anthocyanidin synthase, ANR =
anthocyanidin reductase, LAR = leucoanthocyanidin reductase; c Polymerization of monomeric flavan-3-ols to oligomeric proanthocyanidins,
PPO = polyphenol oxidase, ? indicates uncertainty in existence/role of (intermediate) compound/enzyme
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Unravelling the biosynthesis of monomeric and oligo-
meric flavanols provides knowledge on the nature of the
phytochemicals. In the case of monomeric and oligomeric
flavanols it becomes obvious why they are not glycosyl-
ated in plants and why there exists a large variety of dif-
ferent oligomeric flavanols. These insights also clarify
why it is an absolute necessity to carefully characterize
commercially available flavanolic preparations used in
medicines, food supplements and cosmetics. Batch-to-
batch consistency allows establishing the cause-and-effect
relationship between the product and its physiological ef-
fect, i.e. the physiological consistency of the preparation.
Therefore, scientific data of a well-characterized flavano-
lic preparation cannot be extrapolated to or associated
with the daily consumption of flavanols via ordinary
foods, because foods contain a wide and unspecific var-
iety of all kinds of flavanols. Dietary intake of flavanols
is relevant only in the context of epidemiological studies
in which average and mean intakes are associated with
the health status of certain populations. In this respect
the association between the consumption of red wine and
cardiovascular mortality may serve as an example [22].
On top of that, during the past 30 years many more epi-
demiological data have become available on the dietary
intake of flavanols and the health of populations.
World-wide daily flavan-3-ol and total flavonoid intake
Monomeric, oligomeric and polymeric flavanols form
one of the most abundant classes of flavonoids and are
almost ubiquitous in the plant kingdom. As such they
are present in a wide variety of vegetables and plant-
derived food products including wine, fruit juices, tea
leafs, cocoa beans, fruits, cereal grains and legume seeds
[23–25]. Among fruits, berries like blackcurrants, blue-
berries, chokeberries, strawberries have been found to
contain the highest amounts of monomeric and oligo-
meric flavanols. Also apples and plums are sources of
monomeric and oligomeric flavanols and are suggested
to contribute to their dietary amount daily consumed
[25]. By combining the latest food composition data-
bases on polyphenols and using dietary recall data of
large population cohort studies estimations of the habit-
ual intake of monomeric and oligomeric flavanols in
Europe were recently published [26–28]. Considerable
differences in the dietary flavanol intake among Euro-
pean countries and geographic regions were observed.
The average total flavan-3-ol intake in Europe was re-
ported to be 369 mg/d [27] with the highest intake in
Ireland (mean: 793 mg/d; median: 701 mg/d) and the
lowest intake in the Czech Republic (mean: 181 mg/d;
median: 69 mg/d). The mean and median intake of
proanthocyanidins (both, oligomers (i.e. 2–10 flavanol
units) and polymers (i.e. > 10 flavanol units)) in Mediter-
ranean countries was calculated to 160 mg/d and
30 mg/d (highest intake in Spain; mean: 175 mg/d, me-
dian: 36 mg/d), respectively. This exceeded the mean
and median intake of countries in central Europe (114
and 26 mg/d, respectively) and northern (Scandinavian)
countries (110 and 25 mg/d, respectively). The lowest
averaged proanthocyanidin intake of all European coun-
tries was found in The Netherlands with 96 mg/d (me-
dian: 19.6 mg/d). Tea, wine, cocoa products, pome (in
particular apples and pears) and stone fruits as well as
berries could be identified as major dietary sources of
proanthocyanidins [26–28]. It was also observed that the
proanthocyanidin intake within populations seems to de-
pend on socio-demographic, anthropometric and life-
style characteristics. Subjects with a higher level of
education, increasing age (44–64 years), being moder-
ately active and without obesity (i.e. body mass index
(BMI) < 30 kg/m2) appeared to consume more proantho-
cyanidins than subjects without formal schooling, youn-
ger than 44 years, being inactive and having an BMI >
30 kg/m2 [28].
In contrast to Europe, adults in the USA seem to daily
consume on average lower amounts of total flavonoids,
flavan-3-ols and proanthocyanidins, respectively. Latest
data from a 24 h food recall in a cohort of 5420 people
above 20 years old indicated a mean total flavonoid in-
take of 251 mg/d of which 81% comprised flavanols
mainly derived from tea [29]. The oligomeric proantho-
cyanidin intake was estimated to range between 60 and
95 mg/d [25, 30]. Apples, chocolate products, grapes,
tea, legumes and wine could be identified as major food
sources. As in Europe, differences in the habitual intake
of proanthocyanidins among adult subgroups appeared
to be associated with sociodemographic factors [30].
Whereas the isoflavonoid intake from soy products by
Asian populations is relatively well documented [31–34],
data on the consumption of monomeric and oligomeric fla-
vanols in Asian countries are lacking. A few studies report
daily amounts of total flavonoids in specific Asian countries
without specifying the intake of oligomeric flavan-3-ols. For
example, in a population of almost 1400 adult Chinese total
flavonoid intake was assessed as 166 mg/d [35]. A case-
control study in Korea middle-aged men revealed that on
average 105 mg total flavonoids were daily consumed of
which 20–23 mg were flavan-3-ols [36]. However, these
data do not provide an estimate of the ingested proantho-
cyanidin quantities, because the reported flavan-3-ols only
comprised monomers. Similarly, a cross-sectional cohort
study including 569 middle-aged Japanese women esti-
mated flavan-3-ol monomer consumption by means of
24 h food records as 386 mg flavan-3-ols (i.e. (-)-epicate-
chin, catechin and epicatechingallate) [37]. Ninety-eight
percent of these flavanols were ingested by tea.
Australian adults were found to daily consume on
average 454 mg total flavonoids of which 92% are flavan-
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3-ols (without any subclass specification) predominantly
derived from tea consumption [38]. A prospective clin-
ical study in 948 Australian women above 75 years
assessed by means of food frequency questionnaires an
average total proanthocyanidin (sum of dimers, trimers,
4–6 mers, 7–10 mers, polymers) intake of 215 mg/d
(range: 18–1728 mg/d) which was mainly associated
with the consumption of fruits, chocolate and alcoholic
beverages [39].
Proanthocyanidin intake data for Middle and South
America can hardly be found. Arabbi et al. determined
the flavonoid content of commonly consumed Brazilian
fruits and vegetables [40]. They also gave an overview on
4 epidemiological studies that indicate that the total ha-
bitual flavonoid intake in Brazilians ranges between 60
and 106 mg/d. They concluded from these studies that
dietary flavonoid sources in Brazil are not very diverse
since more than 70% of flavonoids are derived from or-
anges, 12% from lettuce and about 3% from tomatoes
[40]. A recent survey estimates total average flavonoid
intakes of 139 mg/d [41]. Despite a lack of data on quan-
tities of subclasses, the identified major flavonoid food
sources included legumes, fruits and beverages which
are known to be rich in proanthocyanidins [24, 25, 42].
However, the total habitual intake of fruits and vegeta-
bles in Brazil appears to be much lower than in other
countries world-wide. Less than 10% of the Brazilian
population daily consumes 400 g fruits and vegetables as
recommended by the WHO [40, 43]. Data on dietary fla-
vonoid intake in African countries are not available in
literature. In view of the discrepancies in chemical no-
menclature, the size and anthropometric composition of
the cohorts, the dietary assessment of food intake, the
estimation of flavonoid and proanthocyanidin content of
national food products by the use of different flavonoid
databases, it is obvious that the reviewed data provide
only rough estimates of the actual dietary intake of
monomeric and oligomeric proanthocyanidins around
the globe. However, it can be concluded with confidence
that monomeric and oligomeric flavan-3-ols are present
in human diets world-wide. Regular consumption of
pome and stone fruits, berries, legumes, tea, wine and
dark chocolate products leads to an intake of several
hundreds of mg per day.
Due to the methodological limitation being associated
with the quantitative assessment of the daily consump-
tion of specific dietary constituents within populations, it
is likely that individual’s intake may be above or below
the population’s average. Since the daily dietary intake of
monomeric and oligomeric flavanols fluctuates in and
between individuals the attribution of health benefits to
daily intakes remains problematic. Therefore, a nutra-
ceutical with a well-defined monomeric and oligomeric
composition, such as Masquelier’s® Original OPCs,
constitutes a relevant alternative since its recommended
use will provide the health benefits that were established
in preparation-specific research.
Chemical composition of Masquelier’s grape seed extract
In order to warrant safety and efficacy of a plant extract,
i.e. pharmaceutical quality and physiological consistency,
the same criteria as for synthetic substances apply, i.e.
identity, purity and content of the material must be estab-
lished batch-to-batch [44]. Quality assurance of plant ex-
tracts is challenging since the raw materials from which
they are obtained are prone to a number of variables that
cannot always be controlled. The spectrum of constituents
of natural materials relies on environmental factors under
which the plant is grown (e.g. soil composition, climate,
pest) as well as processing procedures (e.g. harvesting,
transportation, drying, storage). Masquelier’s® Original
OPCs exemplify how pharmaceutical-grade quality of a
plant extract can be achieved. Table 1 provides an over-
view on the properties and methods used to assess the
identity, composition and purity of the extract. The prepa-
ration’s identity is established by organoleptic and spectro-
photometric characteristics, e.g. the polyphenols’
absorbance maxima of λ = 220–280 nm. The purity of the
preparation is determined by moisture, ash, physical con-
stants, solvent residues, microbiological contaminations,
foreign materials (e.g. heavy metals, pesticide residues, af-
latoxins) and adulterations (Table 1).
The extract’s specification of the content requires the
qualitative and quantitative analysis of the phytochemicals.
Various colorimetric though unspecific assays have a long
tradition to determine the presence of polyphenols in gen-
eral. The Folin-Denis and the Folin-Ciocalteau reagents,
respectively are largely used to quantify total polyphenolic
content of plant materials [45]. Both reagents rely on the
oxidation of phenolic compounds in alkaline solution and
subsequent reaction to blue colored phosphotungstic-
phosphomolybdenum complexes which absorb at a wave-
length of around λ = 760 nm. By means of the reference
polyphenol gallic acid total polyphenolics are quantified as
gallic acid equivalents (GAE) per kg or liter extract. As
shown in Table 2 the total polyphenolic content of
Masquelier’s grape seed extract amounts to 90–95% ac-
cording to spectrophotometry and the Folin-Ciocalteau
method. Drawbacks of this method are that not all plant
phenolics are detected with the same sensitivity and that
with regard to mono- and/or oligomeric flavanols, it is
useless since it is unspecific and cannot provide any infor-
mation in terms of the various flavanolic fractions in ex-
tracts. Moreover, sugars, aromatic amines and ascorbic
acid can interfere with the color reaction [46].
The commonly used colorimetric method to deter-
mine the presence of proanthocyanidins is n-butanol/
HCl hydrolysis to red colored anthocyanidins which
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have an absorbance maximum at around λ = 550 nm
[47, 48]. Due to numerous technical limitations it was
recommended to use this assay to detect the presence of
oligomeric flavanols rather than to quantify them [49].
Another limitation is that the Bate-Smith reaction does
not differentiate between specific fractions of proantho-
cyanidins. The coloration is produced by all proanthocya-
nidins, oligomers and polymers, i.e. irrespective of their
level of polymerisation. For the purpose of quantifying
total proanthocyanidins in a preparation, the vanillin assay









UV spectrum (approx. 40 mg/L in ethanol 96%) λ max = 280 ± 5 nm
λ min = 256 ± 5 nm
Bate-Smith reaction (approx. 100 mg/L) λ max = 540–550 nm
Loss on drying ≤10% Ph. Eur. 01/2005: 20817
Sulphated ashes ≤0.5% Ph. Eur. 01/2005: 20414
Solubility conform Ph. Eur. 6.7: 51100
1% (w/v) in water insoluble < 5%
2% (w/v) in methanol Soluble
1% (w/v) in isopropanol Soluble
0.01% (w/v) in chloroform Insoluble
pH (4% (w/v) in water) 2.5–4.5 In house




ethyl acetate ≤10 ppm
n-butanol ≤10 ppm
Microbiology conform Ph. Eur. 6.7: 50104
Bacteria <10000 cfu/g
Enterobacteria <100 cfu/g
Escherichia coli 0 cfu/g
Staphylococcus aureus 0 cfu/g
Salmonella 0 cfu/10 g
Pseudomonas aeruginosa 0 cfu/g
Yeasts and moulds <100 cfu/g
Mycotoxins Comply with Reg. EC 1881/2006 In house
Pesticide/phytosanitary products a ≤0.05 ppm Ph. Eur. 6.7: 20813
Heavy metals (Fe, Cd, Hg, Pb, As) <1 ppm Ph. Eur. 6.7: 20408
Polychlorinated biphenyls and dioxins Comply with Reg. EC 1881/2006 In house
a The EU has established Maximum Residue Limits (MRL) of pesticides for “certain products of plant origin” (Directive 90/642/EC incl. amendments and corrections).
The investigated phytosanitary products include aldrin; 4,4’-dichlorodiphenyldichloroethane; 4,4’- dichlorodiphenyldichloroethylene; 2,4’-
dichlorodiphenyltrichloroethane; 4,4’- dichlorodiphenyltrichloroethane; dieldrin; α-endosulfan; β-endosulfan; endrin; α-hexachlorocyclohexane; β-
hexachlorocyclohexane; γ-hexachlorocyclohexane; heptachlor; trans-heptachlor epoxide; hexachlorobenzene; methoxychlor
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might be a slightly better colorimetric alternative. In the
presence of sulfuric acid vanillin reacts with condensed
flavan-3-ols (oligomers and polymers) to a red colored
complex that can be measured at a wavelength of λ =
500 nm. Usually, catechin is used as a reference substance
although for the quantification of polymerized flavanols
internal standards would be more advantageous to ac-
count for different reaction rates of monomers and oligo-
mers [50]. Various factors influencing the outcomes of the
vanillin assay were identified [49], and led to a meticulous
reexamination of the assay [50]. By means of this vanillin
method the total proanthocyanidins content of Masque-
lier’s Original OPCs amount to 60–70% (Table 2). None-
theless, the major disadvantage of all these
spectrophotometric assays is that they solely provide an
estimation of the total polyphenolic and/or proanthocya-
nidin content of extracts. Individual fractions cannot be
qualified or quantified by these methods. For this purpose,
high performance liquid chromatography (HPLC) is the
preferred technique. Several excellent reviews have been
published over the last years that provide an overview on
HPLC methods for the quantification of polyphenols as
wells as a critical appraisal of factors that are essential to
take into account for reliable measurements [46, 51–53].
In 1990, Masquelier and his team developed an HPLC
method to analyze the monomeric and oligomeric flavanol
content in grape seed and pine bark extracts [54]. To iso-
late and identify the individual monomeric and oligomeric
flavanols the crude plant extract was first purified by solid
phase extraction (SPE) on Sephadex G25 and LH20
columns and by semi-preparative HPLC. Fifteen flavanol
monomers and oligomers could be identified by chemical
(acidic degradation in the presence of α-toluenethiol) and
spectroscopic techniques like nuclear magnetic resonance
(NMR), ultraviolet-visible (UV/VIS) and infrared (IR) [55].
Next to the monomers (+)-catechin, (-)-epicatechin and
(-)-epicatechin gallate, 6 dimers of the B-series were
found, i.e. proanthocyanidin B1, B2, B3, B4, B5 and B7
and 1 dimer of the A-series, i.e. proanthocyanidin A2.
Moreover 4 trimers have been identified, i.e. (+)-catechin
- (+)-catechin - (+)-catechin, (-)-epicatechin - (-)-epicate-
chin - (-)-epicatechin, (-)-epicatechin - (-)-epicatechin -
(+) catechin and (-)-epicatechin - (-)-epicatechin - (-)-epi-
catechin-gallate (EEEg) as well as a tetramer consisting of
(-)-epicatechin - (-)-epicatechin - (-)-epicatechin - (-)-epi-
catechin [54]. Later, the preparation’s manufacturer (Ber-
kem SA; Gardonne; France) in collaboration with the
University of Bordeaux repeated and modified Masque-
lier’s analyses by using a C18 base-deactivated reversed-
phase column (e.g. ProntoSIL 120-5-C18H, Bischoff Chro-
matography, Leonberg, Germany) with a gradient elution
system of water/trifluoroacetic acid (TFA) 0.005% (v/v)
and acetonitrile 65% (v/v)/TFA 0.005% (v/v) at a flow rate
of 0.7 ml/min, at ambient column temperature and with
UV detection at a wavelength of λ = 280 nm. In the chro-
matogram obtained mainly the monomeric and dimeric
compounds are identified (Fig. 4), although centrifugal
partition chromatography (CPC), preparative HPLC,
NMR and mass spectrometry allowed the identification of
14 monomeric, dimeric and trimeric flavan-3-ols in
addition to gallic acid. This HPLC analysis can be used to
routinely monitor the composition of the grape seed ex-
tract next to 1H-NMR spectroscopy followed by principle
component analysis (PCA) as described below. Batch-to-
batch analyses revealed that approximately a fourth of the
grape seed extract’s flavanols is made up by monomers, a
second fourth are dimers and half of the extract consists
of trimers, tetra- and pentamers (Table 3). Normal phase
(NP)-HPLC demonstrated the absence of higher polymer-
ized flavanols [56]. The qualitative and quantitative ana-
lysis of the grape seed extract is an important prerequisite
to control and achieve a constant, standardized phyto-
chemical composition. The HPLC data revealed that the
Masquelier’s extract is a complex mixture of individual
flavanols of various polymerization degrees (n = 2–5).
Monitoring batch-to-batch variations of the preparation
based on only one flavanol would be inadequate because
changes in one specific flavanol might not be representa-
tive for all the different individual flavanolic fractions.
Since the physiologically active principle of a plant extract
is the entire mixture of individual phytochemicals and not
a single compound, profiling the whole spectrum of phy-
tochemicals in the grape seed extract is necessary to guar-
antee a stable composition and ultimately consistent
Table 2 Analysis of the flavanol content of Masquelier’s grape seed extract. The data were provided by the extract’s manufacturer
Compound Analytical method Content
Total polyphenols Spectrophotometric (GAE), n = 3 90–95%
Folin-Ciocalteau reagent (GAE), n = 3
Flavan-3-ols Vanillin-H2SO4 (Sun et al., [50]), n = 9 60–70%
HPLC, n = 14
Monomeric flavanols HPLC (every batch) 25–30%
Oligomeric flavanols (2–5 units) HPLC (every batch) 35–40%
Polymeric flavanols (>6 units) HPLC (every batch) 1–5%
GAE gallic acid equivalence, HPLC high performance liquid chromatography
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bioactivity. NMR spectroscopy is a versatile analytical tech-
nique to screen complex composed samples with minimal
and non-destructive sample preparation. Standard 1H- or
13C-NMR spectra provide a wealth of information on both,
chemical structures of individual compounds and chemical
profiles of compound mixtures. That makes it increasingly
popular for elucidation of novel plant-derived compounds
as well as for characterization of plant extracts and food
products [52]. All molecules containing atoms with a non-
zero magnetic moment (e.g. 1H, 13C, 14N, 15N, 19F, 31P) give
an unique NMR signal which originates from the structural
location of these atoms in the molecule. NMR analysis of
an extract with a complex mixture of plant metabolites
provides a unique spectrum of signals, i.e. a fingerprint,
depending on its molecular composition (Fig. 5a). Multi-
variate analysis of such unassigned fingerprint NMR-
spectra is a convenient and accurate tool to compare the
phytochemical content of different plant extracts e.g. from
distinct manufacturers or from different batches [57].
Therefore, 1H-NMR spectroscopy followed by PCA [58] is
used to control batch-to-batch consistency of Masquelier’s
grape seed extract. The yellow dots in the three-
dimensional plot (Fig. 5b) represent the 95% confidence in-
tervals of each batch analysis and form a clearly separated
cloud indicating high similarity of the phytochemical
NMR-profile of the individual batches. This cluster of Mas-
quelier`s grape seed extract batches (Anthogenol®, yellow)
clearly distinguishes from the cluster of French pine bark
extracts (M-PM, red) and other grape seed extracts (GSEs,
magenta). Samples of the Endotélon extract (red) and sam-
ples of Masquelier’s extract from 1985 (VV-OPC 1985, yel-
low) are located within the “Anthogenol” cluster proving
the qualitative and quantitative equality of these extracts
and its consistency throughout the years. The application
of NMR fingerprinting enables to continuously authenticate
the extract and allows for the production of a genuinely
standardized product. Eventually, this is essential for
safeguarding the preparation’s physiological consistency.
Lacking standardization and characterization of the
phytochemical composition of herbal extracts makes
Fig. 4 Representative chromatogram of Masquelier’s grape seed extract measured by high performance liquid chromatography (HPLC) using a C18
base-deactivated reversed-phase column (e.g. ProntoSIL 120-5-C18H, Bischoff Chromatography, Leonberg, Germany) with a gradient elution system of
water/trifluoroacetic acid (TFA) 0.005% (v/v) and acetonitrile 65% (v/v)/TFA 0.005% (v/v) at a flow rate of 0.7 ml/min, at ambient column temperature
and with UV detection at a wavelength of λ = 280 nm. The peaks in the chromatogram have been identified as the following individual monomeric
and oligomeric flavan-3-ols: 1 = procyanidin B1, 2 = procyanidin B3, 3 = (+)-catechin, 4 = dimeric procyanidin consisting of (+)-catechin-(-)-epicatechin,
5 = procyanidin B4, 6 = procyanidin B2, 7 = (-)-epicatechin, 8 = prodcyanidin B2 gallate. The data were provided by the extract’s manufacturer
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studying the in vivo biotransformation of the plant-de-
rived constituents cumbersome. With a meticulously de-
fined product, such as Masquelier’s flavanol blend, it
becomes feasible to study the bioavailability and
metabolism.
Bioavailability and metabolism of Masqulier’s grape seed
extract
Knowledge on the bioavailability, biotransformation and
kinetics of grape-seed derived flavan-3-ols is important
for the elucidation of their mechanism of action. In
addition, these data strengthen the cause-effect relation-
ship between the (recommended) dietary intake and the
observed health effect of these compounds. In order to
shed more light on the fate of orally ingested monomeric
and oligomeric flavan-3-ols, animal experiments were
conducted in the late 70ies of the last century. Radiola-
beled monomeric and oligomeric flavan-3-ols (0.6 μCi
(0.2 × 10^3 Bq)/mg) could be obtained from the seeds of
grapes (Vitis vinifera L. of the Cabernet and Merlot
variety) grown during grape formation in a 14CO2 at-
mosphere for 40 days. After oral administration of a sin-
gle dose of 2 μCi (approximately 3.3 mg grape seed
extract) radioactivity in blood of mice (n = 5) was mea-
sured at 9 consecutive time points between 10 min and
7 h [59, 60]. Following a rapid increase in the blood’s
radioactivity, maximal plasma levels were reached
45 min. after ingestion. The plasma half-life was esti-
mated to 5 h. The distribution of the flavanols in the
mice was determined in various types of tissue collected
at 1, 3, 6 and 24 h after intake of a single oral dose
(5 mg) [59, 60]. During the first 6 h most of the
radioactivity was located in the gastro-intestinal tract in-
cluding gall-bladder and bladder. Lower levels of radio-
activity could be detected in the liver, kidneys, skin,
cartilage tissue, arteries, cardiac muscle and blood. After
24 h the gastro-intestinal tract was free of any radio-
activity. In contrast, radioactivity was markedly elevated
in the gastro-intestinal vasculature, arteries, skin, and
cartilage tissue. Decreasing levels of radioactivity were
seen in liver, spleen, venous tunica, periost, kidneys,
lungs, bones and blood. Repeated daily dosages over 5
consecutive days did not seem to lead to an accumula-
tion of the flavanols in mice [59, 60]. In rats (n = 5) bile
was found to be essentially involved in the elimination
of monomeric and oligomeric flavanols [59, 60]. The use
of semi-synthetically produced 3H-labeled flavan-3,4-diol
monomer confirmed the tissue distribution of the 14C-
labeled grape seed flavanols. Since 3H-radioactivity
remained measurable in mice tissue sections, especially
in collagen-rich types of tissue, it was suggested that tis-
sue binding of flavanols neither involves the hydroxyl-
group in the C4-position of the flavan-moeity (C-ring)
nor in situ polymerization of flavanol-monomers via the
C4-position [59, 60]. Although these early experimental
data indicate that grape-seed-derived monomeric and
oligomeric flavanols become bioavailable upon oral inges-
tion, it remained unknown in which form, i.e. as parent
compounds or metabolites, they are distributed in the body.
Moreover, it remains to be elucidated whether bioavailabil-
ity and biotransformation routes differ between rodents
and humans as reported for other types of flavonoids [61].
Table 3 Mean quantities ± standard deviation (SD) of monomeric and oligomeric flavan-3-ols of 10 batches of Masquelier’s grape
seed extract measured by high performance liquid chromatography (HPLC, see also Fig. 4). The data were provided by the extract’s
manufacturer
Compound Mean quantity ± SD (% (w/w))
Total monomers 25.6 ± 2.2
(+)-catechin 10.9 ± 1.6
(-)-epicatechin 12.2 ± 1.6
(-)-epicatechin-3-O-gallate 2.5 ± 1.6
Total dimers 27.5 ± 1.6
Procyanidin B1 7.7 ± 1.6
(-)-epicatechin-(4 β→ 8)-(+)-catechin
Procyanidin B2 8.3 ± 1.6
(-)-epicatechin-(4β→ 8)-(-)-epicatechin
Procyanidin B3 2.8 ± 1.6
(+)-catechin-(4α→ 8)-(+)-catechin
Procyanidin B4 1.6 ± 1.6
(+)-catechin-(4α→ 8)-(-)-epicatechin
Procyanidin B2-gallate 7.1 ± 1.6
Total tri-, tetra- and pentameric proanthocyanidins 46.9 ± 1.6
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In a preliminary human pharmacokinetic study with
14C labelled grape seed mono- and oligomeric flavanols
(Endotélon®), 6 healthy volunteers received a single oral
dose of 150 mg in the morning under fasting conditions
[62]. Plasma radioactivity was in general low and found
to be in the range of ng equivalents of the administered
dose. Despite considerable inter-individual differences
maximal radioactivity plasma levels were observed at ap-
proximately 14 h after flavanol administration with a
slow decrease over the subsequent 144 h. During 96 h
after intake between 11 and 27% (mean ± SD = 22.09 ±
5.99%) of the oral dose was eliminated via urine and
between 22 and 67% (mean ± SD = 45.61 ± 14.92%) via
feces. On average approximately 6% of the flavanols was
measured in breath as 14CO2 with the majority exhaled
during the first 24 h [62].
One major drawback of those studies is that they do
not provide any information on the origin of the 14C la-
belled radioactivity in tissue, i.e. whether it derives from
the ingested parent compounds or from metabolites.
Thereby it remains unclear in which form flavanols
reach target tissue and may be responsible for putative
health effects. The development of highly sensitive ana-
lytical techniques such as HPLC coupled to mass spec-
trometric (MS) detection has considerably increased
insights in the metabolic fate of monomeric and oligo-
meric flavanols. Today it is possible to quantify flavanols
in the fmolar range in various types of matrices and at
the same time to elucidate their molecular structure.
This has considerably advanced the knowledge on the
absorption, distribution, metabolism and excretion of
flavanols. Animal studies reported flavanolic monomers,
dimers and trimers in plasma, urine and feces of rats or-
ally administered with grape seed extracts [63–66]. In
these in vivo studies the major biotransformation routes
comprised methylation, glucuronidation and sulphation
of both, monomeric and oligomeric flavanols [64–66].
Data on the bioavailability and metabolism of grape seed
derived flavanols in humans are scarce. A recent perfu-
sion study revealed that the absorption of a single 50 mg
dose of the flavanolic monomer (-)-epicatechin varies
between healthy persons ranging between 31 and 90%
[67]. Glucuronidation, sulphation and methylation pro-
duce the major epicatechin metabolites that can be
found in plasma approximately 2 h after oral ingestion
[68] and which are excreted in bile and in urine [67].
Plasma concentrations of untransformed epicatechin
have been reported to be around 1% of the epicatechin
sulfate metabolites and amount to approximately 4 nM
1 h after ingestion of a cocoa dairy-based drink provid-
ing 1.8 mg epicatechin per kg body weight [68]. In con-
trast to monomers human data on the fate of oligomers
are less consistent. Dimeric B-type proanthocyanidins
have been detected in nmolar quantities in the circula-
tion after a single dose of 323 mg cocoa-derived mono-
mers and 256 mg dimers [69] and 2 g of a grape-seed
extract [70], respectively. However, higher condensation
products are assumed not to be absorbed due to their
molecular weight, although in vitro and in vivo studies
showed the absorption of the proanthocyanidins trimer
C2 [64, 66, 71]. Trimeric and larger condensation prod-
ucts are generally suggested to undergo colonic degrad-
ation to phenolic acids [72] and valerolactones [73, 74],
rather than to serve as monomer precursors [68, 75].
Therefore, based on the current data it needs to be pre-
sumed that the intake of grape seed extract containing
a
b
Fig. 5 a Typical examples of an unassigned fingerprint proton nuclear
magnetic resonance (1H-NMR) spectra of Masquelier’s grape seed
extract (1) and another grape seed extract (2). b Three-dimensional plot
of the principle component analysis (PCA) using unassigned fingerprint
proton nuclear magnetic resonance (1H-NMR) spectra to compare the
phytochemical content of different plant extracts e.g. from distinct
manufacturers or from different batches. The small white dotted lines
indicate the 95% confidence interval per cluster. The cluster of
Masquelier’s grape seed extract (Anthogenol®, yellow) clearly
distinguish from the cluster of French pine bark extract (M-PM, red)
and other grape seed extracts (GSEs, magenta). Samples of the
Endotélon extract (red) and samples of Masquelier’s extract from 1985
(VV-OPC 1985, yellow) are located within the cluster of Masquelier’s
grape seed extract proofing the qualitative and quantitative equality of
these extracts. The green-blue lines represent the 3 strongest principal
components (PC), i.e. the variables derived from the 1H-NMR spectra
which define the biggest differences between all the samples. The
farther 2 samples are apart from each other in respect of one particular
axis, the more different they are in this particular aspect. The data were
provided by the extract’s manufacturer
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both, monomeric and oligomeric flavan-3-ols, will lead
to monomeric phase II conjugates and colonic biotrans-
formation products in the human circulation. It remains
to be elucidated in how far these metabolites contribute
to the observed health effects.
Over the past decades, the state of the art of analyt-
ical-chemical techniques increased considerably. These
technical advances revealed that the historical data
using radioactive-labelled grape seed flavanols lacks spe-
cificity. Thereby, the precise metabolic fate and kinetic
profile of Masquelier’s grape seed extract is still incom-
plete. Whether flavanol-tissue binding takes place as
concluded by Laparra et al. [59, 60], remains question-
able. Still, the fact that proanthocyanidins bind to colla-
gen-rich tissues has been well established. Polymers of
proanthocyanidins are called tannins because of their
“tanning” properties. Tannins strongly bind to collagen-
rich tissue (leather). This millenia-old knowledge forms
an indication that part of the oligomers’ protective mode
of action may stem from their affinity to collagen. In this
regard, separate from the kinetic profiling of flavanolic
plant extracts, their physiological mode of action is key
in developing the product as a nutraceutical.
Mechanisms of action of Masquelier’s grape seed extract
Effects on collagen and elastin fibers in vitro and in vivo
The time-journey of Masquelier’s monomeric and oligo-
meric flavan-3-ols extract started with the observation of
their effect in vascular tissue. With other grape seed ex-
tracts many other, often similar studies have been done.
It is, however, known that grape seed extract may vary
widely in the way they are composed (vide supra) as
nicely illustrated by Nakamura et al. [76]. It is therefore
important to use a well-characterized grape seed extract
with a stable composition. Since composition affects bio-
logical activity, in the description of the mechanisms of
action we limit this review to the available data on Mas-
quelier’s extract. The microcirculatory effect of Masque-
lier’s monomeric and oligomeric flavanol extract was
correlated to the original findings that the preparation
protects collagen. The stability of collagen depends on
the cross-linking of the peptic chain in the molecule.
Denaturation of the molecule, for example by increased
temperature or oxidative stress, leads to shortening of
the collagen fibers. In vitro, Masquelier’s® Original OPCs
have been shown to protect against the thermal contrac-
tion of the collagen [77]. Of all bioflavonoids only the
proanthocyanidins (oligomeric flavanols) seem to exert
this protecting effect which might be due to the vari-
ation in their cross-linking effect. Oligomeric flavanols
show strong collagen protection and isotopic labelling of
monomeric and oligomeric flavan-3-ols can be inter-
preted as a confirmation of the oligomers’ affinity for the
vascular wall (vide supra) [60]. This was also confirmed
in 1982 by A. Pfister et al. who studied the localization
of monomeric and oligomeric flavanols in cell mem-
branes of endothelial cells and pneumocytes [78].
Similarly, the risk of vascular damage can be re-
duced by Masquelier’s grape seed extract through the
protection of elastin from degradation by elastase in
vitro and in vivo. In vitro, the solubilization of elastin
obtained from calf articular ligament by either elas-
tase from porcine pancreas or human leukocyte was
inhibited by incubating the elastin with the extract.
Also in vivo, after intradermal injections of the
flavanols in the skin of rabbits, it was shown that this
pretreatment protected the elastin [79]. The inhibition
of the hydrolysis of elastin by elastase and of collagen
by collagenase has been confirmed in other in vitro
models [80]. There are even indications that the syn-
thesis of collagen and elastonectin fibers is promoted
by the extract in vitro [80] and in vivo [78].
This antiproteolytic activity offered by the oligomeric
flavan-3-ols present in the preparation has been classi-
fied as ‘substrate protection’, because the compounds do
not primarily inhibit the proteinases that degrade the
matrix-components but rather bind to the matrix mac-
romolecules thus preventing degradation by various trig-
gers such as temperature, oxidative stress, inflammation,
proteinases among others [81].
In Wistar rats, collagenase-induced vascular capillary
hyperpermeability was inhibited by the grape seed
derived monomeric and oligomeric flavanols [80]. The
flavanols’ strengthening effect on collagen- and elastin-
rich tissues like blood vessels and the venous system has
also been demonstrated in various human intervention
studies as reviewed in 2003 [82].
Antioxidant effects in vitro and in vivo
With the discovery that reactive oxygen species play a
pivotal role in the aging physiology a lot of attention
was given to this research area [83]. Also vascular
function is strongly influenced by oxidative stress
[84]. The imaginative studies in the early fifties of the
previous century already demonstrated that the oxida-
tion of the antioxidant vitamin C could be prevented
by Masquelier’s extract [85]. The established action of
the flavanols on vascular function directed the re-
search to the field of prevention and attenuation of
oxidative stress and ever since the antioxidant action
of monomeric and oligomeric flavan-3-ols has indeed
been widely studied. In 1987, the US Patent Office
granted Jack Masquelier a patent for the use of
proanthocyanidins as antioxidants in various fields of
human physiology [86].
Polyphenolic structures are known to be good antioxi-
dants [87]. Monomeric and oligomeric flavanols have
been shown to have radical scavenging activity, e.g.
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scavenging of the 2,2-diphenyl-1-picrylhydrazyl (DPPH)
radical [88] and the superoxide anion radical [89, 90].
Moreover, monomeric and oligomeric flavan-3-ols pro-
tect against hydrogen peroxide [91] and organic perox-
ide (i.e. cumene hydroperoxide)-induced damage of fetal
bovine vascular endothelial cells [92]. Iron (Fe2+- adeno-
sine diphosphate (ADP)) in combination with ascorbic
acid leads to lipid peroxidation in rat liver microsomes,
which is inhibited by monomeric and oligomeric flavan-
3-ols [89, 93].
Monomeric and oligomeric flavan-3-ols are clearly and
not unexpectedly (based on the molecular structure of
the constituents) able to scavenge reactive oxygen and
nitrogen species and inhibit lipid peroxidation. Due to
the low concentrations that are found in the human cir-
culation after flavanol supplementations (vide supra), the
relevance of direct antioxidant effects of these com-
pounds under physiological conditions is increasingly
debated. However, we recently demonstrated that also
epicatechin phase II metabolites attenuate intracellular
oxidative stress in primary human umbilical vein endo-
thelial cells (HUVECs) in concentrations as low as
0.5 μM [94].
With the progressing insights into redox regulation of
cell signaling during the last decades, studies aimed at
unraveling the effects of monomeric and oligomeric fla-
vanols on redox-sensitive transcription factors like nu-
clear factor (erythroid-derived 2)-like 2 (Nrf2). Nrf2 is
critical in the transcriptional regulation of genes coding
enzymes that facilitate cellular protection against oxidative
stress. In hepatocytes it was recently shown that epicate-
chin transiently activates, among other redox-sensitive
transcription factors, Nrf2 [95]. Similarly, procyanidin B2
activated redox-sensitive signaling cascades involved in
the activation of Nrf2, induced the translocation of Nrf2
from the cytoplasm into the nucleus and activated the
transcription of the detoxifying enzyme glutathione S-
transferase pi 1 (GSTP1) in in epithelial colon cells [96].
Interestingly, Nrf2 activation and modulation of Nrf2-
mediate gene transcription was reported in various in
vitro and in vivo models by monomeric and oligomeric
flavanol-rich extracts of different plants sources [97–99]
including grape seeds [100, 101].
Nowadays, it is well established that diminishing
oxidative stress also reduces the inflammatory response.
A vicious interplay between oxidative stress and inflam-
mation is apparent. In fact, inflammation is probably
fundamental in many pathologies and maintaining
health is achieved by keeping the inflammation low.
Anti-inflammatory effects in vitro and in vivo
Monomeric and oligomeric flavan-3-ols inhibit the in-
flammatory response also in a more direct way.
Leukocyte-induced luminescence stimulated with either
zymosan or the phorbol ester phorbol12-myristate 13-
acetate (PMA) was dose-dependently inhibited by the
monomeric and oligomeric flavanols preparation [88].
Also in animal experiments the anti-inflammatory effect of
Masquelier’s extract has been demonstrated. Blaszò et al.
reported that in a carrageenan-induced rat paw oedema
model the intraperitoneally administered preparation in
dosages of 10, 20, 40 mg/kg displayed an anti-
inflammatory action [102]. Oral administration of rats with
500 mg/kg Masquelier’s Original OPCs® also gave protec-
tion against the carrageenan paw oedema effect [88].
More than 20 years later, the anti-inflammatory effects
of the grape-seed derived monomeric and oligomeric
flavanols were further explored on a cellular and subcel-
lular level. The transcription factor nuclear factor kappa-
light-chain enhancer of activated B cells (NF-κB) is the
key regulator of the transcription and synthesis of in-
flammatory mediators in immune cells [103]. In human
monocytes (U937 cells) which were stably transfected
with a luciferase-reporter gene construct containing NF-
κB binding sites and which were differentiated into
macrophage-like cells the inhibition of NF-κB-mediated
gene expression by the grape-seed derived monomeric
and oligomeric flavanols was demonstrated [104]. That
this subcellular effect has consequences for the function
of human monocytes was proven in an assay that allows
studying the chemotaxis and adhesion of monocytes to
vascular endothelial cells [104]. Preincubation of the
monocytes with the grape-seed derived monomeric and
oligomeric flavanols for 24 h reduced the number of ad-
hering cells at the endothelial cells by approximately one
third [104]. These data shed light on a molecular mech-
anism of the grape-seed derived flavanolic preparation
that may help to explain their anti-inflammatory activity
observed in humans (vide infra).
Moreover, (-)-epicatechin was recently suggested to
enhance the anti-inflammatory effects of the endogenous
glucocorticoid cortisol in human macrophage-like cells
under oxidative stress [105]. Next to the parent com-
pound also epicatechin phase II metabolites exhibit cap-
acity to preserve the anti-inflammatory effects of cortisol
in this model [106]. This mechanism is an eminent ex-
ample of the intertwined link between oxidative stress
and the development of inflammation by a compromised
endogenous cortisol response. In how far Masquelier’s
extract exert similar protection of the cortisol response
must be demonstrated.
As illustrated here, Masquelier’s flavanol blend show a
multitude of biological effects. This is distinctive from
most pharmaceuticals that are generally selected for their
strong effect on a well-defined single molecular target.
The efficacy of drugs in humans is determined in clinical
trials by a statistical change in a primary outcome par-
ameter indicative for an improvement of a disease. In
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contrast, to capture the multiple - pleiotropic - effects of
botanical extracts a broad panel of biomarkers is re-
quired. Moreover, effects on human health are character-
ized by the ability to withstand a stressor in the
physiological system and maintain or restore homeostasis
[107]. The relevance of results from human intervention
studies should therefore be judged from this perspective,
i.e. whether the observed effects are the result of inte-
grated physiological phenomena.
Effects of Masquelier’s grape seed extract on human
health
Initially, several clinical studies on the protective effect
of Endotélon® (the French herbal remedy consisting of
Masquelier’s grape seed extract) on capillary fragility
were performed. Dartenuc et al. reported in an open-
label study using 100 – 150 mg/d of Endotélon® for 30 –
45 days a reduction in capillary fragility in 39 out of 46
subjects assessed by a cupping glass method [108]. To
confirm these findings, the researchers performed a sec-
ond study which was placebo-controlled. The daily in-
take of Masquelier’s grape seed preparation for 15 days
improved capillary fragility in 10 of 21 volunteers,
whereas in the placebo-group a similar effect was only
seen in 3 out of 12 subjects [108]. The capillary resist-
ance defined as the property of capillaries to counteract
the forces of rupture was improved by the intake of
100–150 mg after 15–30 day of intervention [109]. The
protection of capillary resistance by Endotélon® was also
demonstrated in a double-blind placebo-controlled study
in subjects with either spontaneous capillary fragility or
acetylsalicylic acid-induced capillary fragility [109]. In a
double-blind placebo-controlled trial the measurement
of skin temperature as a measure of dermal circulation
and rheographic parameters were used to show an im-
proved venous tone in subjects who daily took 150 mg
of Masquelier’s preparation (Endotélon®) for 45 days
[110]. During 15–90 days Beylot C. and Bioulac P. ad-
ministered patients with a variety of problems related to
capillary fragility 150 mg Endotélon® per day and ob-
served a decrease in fragility in 62 out of 78 subjects
[111]. In patients with varying phlebologic disorders the
influence of Endotélon® on edema, varicose veins, hypo-
dermitis, capillaries and petechies was investigated by a
placebo-controlled randomized clinical trial [112]. The
daily intake of 150 mg Endotélon® over 4 weeks im-
proved edema and varicose veins compared to the
placebo treatment. In a homogenous study population of
92 patients with a mean age of 40 years and a venous
pathology of in average 7 years obtained 300 mg Endoté-
lon® for 4 weeks [113]. Clinical scoring of the amelior-
ation was achieved in 75% of the patients (versus 41% in
the placebo group, P < 0.01). Also, edema reduction was
apparent.
The most recent clinical data of Masquelier’s grape
seed extract (embodied in the food supplement Antho-
genol®) were obtained in a double-blind randomized
placebo-controlled clinical study in healthy volunteers
[114]. This study aimed at capturing the diverse effects
of the grape seed-derived monomeric and oligomeric fla-
vanols observed in all the previous studies by a broad
panel of outcome parameters reflecting vascular function
as well as cellular and subcellular processes in the hu-
man vasculature associated with cardiovascular patholo-
gies. For this purpose, 28 male healthy smokers were
daily supplemented for 8 weeks with 200 mg Masque-
lier’s® Original OPCs. Neither macrovascular function
(assessed as flow mediated dilation of the brachial
artery) nor microvascular function (measured by laser-
Doppler flowmetry) changed significantly during the
8 weeks intervention compared with the placebo-
supplemented group. Individuals with elevated total
cholesterol and low density lipoprotein (LDL) serum
concentrations in the beginning of the trial revealed a
5% and 7% reduction (P < 0.05 vs. baseline), respectively
after 8 weeks supplementation with Masquelier’s prepar-
ation. These effects could not be observed in a similar
subgroup on placebo. Whereas platelet aggregability
remained unaffected, a significant attenuation of the in-
flammatory responsiveness of leukocytes to ex vivo
added bacterial endotoxin (compared to baseline and
compared to the placebo intervention) was found in
blood from volunteers after the 8 weeks supplementa-
tion with Masquelier’s® Original OPCs. While total anti-
oxidant capacity of plasma and the lipid peroxidation
marker 8-iso-prostglandin F2α did not change during
the intervention, erythrocytes’ ratio of reduced to oxi-
dized glutathione appeared to increase in the supple-
mented group compared to baseline. Integration of all
the effects assessed by the meticulously selected param-
eter panel into a global vascular health index revealed a
significant increase upon the 8 weeks supplementation
with Masquelier’s grape seed extract compared to pla-
cebo. In order to elucidate the underlying molecular
pathways which might be involved in the observed
changes, RNA and DNA was isolated from leukocytes of
a subset of the volunteers to determine genome wide
changes in gene expression and DNA methylation [104].
The dietary intervention with Masquelier’s extract seemed
to affect in particular the expression of genes associated
with pathways involved in the regulation of inflammation
and chemotaxis, adhesion and transendothelial migration
of leukocytes. Experimental models substantiate these
findings by demonstrating the extract-mediated inhibition
of the inflammatory transcription factor NF-κB [104]. This
mechanism may also contribute to the reduced adhesion
of monocytes exposed to the grape seed-derived flavanols
to vascular endothelial cells in vitro [104]. Despite clear
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effects of the daily supplementation with 200 mg Masque-
lier’s® Original OPCs over 8 weeks on the expression of
genes associated with pathophysiological mechanisms in
the cardiovascular system, the transcriptomic changes
could not be related to alterations in the DNA methyla-
tion state due to high inter-individual variability in leuko-
cytes DNA methylation [104].
This beneficial modulation of inflammatory, metabolic
and redox pathways in the vasculature and the very re-
cently reported effects of a grape seed extract on liver
nicotine adenine dinucleotide (NAD+)-metabolism and
expression of the protein deacetylase sirtuin 1 [115] may
hold promise to extend the clinical investigations on this
extract in the future also to hepatic, endocrine and cog-
nitive health.
Conclusion
The three requirements to substantiate the health bene-
fit of a food product include 1) the characterization of
the product, 2) the clear definition and understandable
wording of the physiological benefit and 3) the plausible
cause-effect relationship between the food product’s in-
take and the health effect.
Ad 1) In contrast to many commercially plant extracts
Masquelier’s grape seed preparation is rigidly defined
and standardized by HPLC and 1H-NMR/PCA finger-
printing. This combination of methods is optimal for
monitoring the quality of plant extracts and is superior
to the analysis of one or more individual “target” compo-
nents of an extract.
Ad 2) The numerous human intervention studies that
became available over time formed the basis for design-
ing an intervention study that employed innovative bio-
molecular techniques and reflects conceptual advances
in nutritional science. This novel approach enabled to
capture the pleiotropic effects of Masqulier’s grape seed
extract on vascular health in humans [114]. This physio-
logical benefit can be briefly worded as “maintenance of
vascular homeostasis”.
Ad 3) Understanding the consistency, dose–response
and biological plausibility of the association between the
vascular health effects and Masquelier’s grape seed ex-
tract is based on the totality of the human intervention
studies. These outcomes are substantiated by experimen-
tal studies that elucidate the molecular mechanisms of
the herbal extract and some of its individual compo-
nents. In this regard, the knowledge on the mode of
action of flavanols in general parallels and supports the
more refined and preparation-specific insights into the
physiological processes described in the studies on the
products that embody the specific monomeric and oligo-
meric flavanols extract developed by Jack Masquelier. In
the quest for unravelling the molecular action of complex
botanical preparations such as Masquelier’s® Original
OPCs, studies are ongoing to enhance our existing know-
ledge and understanding in the intricately related fields of
nutrition, physiology, health and disease. The preparation’s
pleiotropic effects explain why and how it can be applied
as an herbal remedy as well as a nutraceutical in the field
of vascular health.
Abbreviations
1H-NMR: Proton nuclear magnetic resonance; ADP: Adenosine diphosphate;
ANR: Anthocyanidin reductase; ANS: Anthocyanidin synthase; BMI: Body mass
index; CPC: Centrifugal partition chromatography; DAHP: 3-deoxy-D-
arabinose-heptulosonic acid-7-phosphate; D-erythrose-P: D-erythrose-4-
phosphate; DFR: Dihydroflavanol-4-reductase; DPPH: 2,2-diphenyl-1-
picrylhydrazyl; F3’H: Flavanone-3’-hydroxylase; F3H: Flavanone-3-hydroxylase;
GAE: Gallic acid equivalence; GSTP1: Glutathione S-transferase pi 1;
HPLC: High performance liquid chromatography; HUVECs: Human umbilical
vein endothelial cells; IR: Infrared; LAR: Leucoanthocyanidin reductase;
LDL: Low density lipoprotein; MS: Mass spectrometry; NAD: Nicotine-adenine
dinucleotide; NADPH: Reduced nicotine-adenine dinucleotide phosphate;
NF-kB: Nuclear factor kappa-light-chain enhancer of activated B cells;
Nrf2: Nuclear factor (erythroid-derived 2)-like 2; OPCs: Oligomeric
proanthocyanidins; PC: Principle components; PCA: Principle component
analysis; PEP: Phosphoenol pyruvate; PMA: Phorbol12-myristate 13-acetate;





This work was financially supported by International Nutrition Company (INC)
BV, Loosdrecht, The Netherlands.
Availability of data and material
Not applicable.
Authors’ contributions
ARW and AB equally contributed to writing and editing the manuscript.
All authors read and approved the final manuscript.
Competing interest
Both authors declare no competing interest.
Consent for publication
Not applicable
Ethics approval and consent to participate
Not applicable
Received: 12 July 2016 Accepted: 23 November 2016
References
1. Nassiri-Asl M, Hosseinzadeh H. Review of the pharmacological effects of Vitis
vinifera (grape) and its bioactive constituents: an update. Phytother Res.
2016;30(9):1392–403.
2. Olaku OO, Ojukwu MO, Zia FZ, White JD. The role of grape seed extract in
the treatment of chemo/radiotherapy induced toxicity: a systematic review
of preclinical studies. Nutr Cancer. 2015;67:730–40.
3. Kasdagly M, Radhakrishnan S, Reddivari L, Veeramachaneni DN, Vanamala J.
Colon carcinogenesis: influence of Western diet-induced obesity and targeting
stem cells using dietary bioactive compounds. Nutrition. 2014;30:1242–56.
4. Ting H, Deep G, Agarwal C, Agarwal R. The strategies to control prostate
cancer by chemoprevention approaches. Mutat Res. 2014;760:1–15.
5. Tong LX, Young LC. Nutrition: the future of melanoma prevention? J Am
Acad Dermatol. 2014;71:151–60.
6. Feringa HH, Laskey DA, Dickson JE, Coleman CI. The effect of grape seed
extract on cardiovascular risk markers: a meta-analysis of randomized
controlled trials. J Am Diet Assoc. 2011;111:1173–81.
Weseler and Bast Nutrition Journal  (2017) 16:5 Page 16 of 19
7. Ho L, Pasinetti GM. Polyphenolic compounds for treating
neurodegenerative disorders involving protein misfolding. Expert Rev
Proteomics. 2010;7:579–89.
8. Pasinetti GM, Ho L. Role of grape seed polyphenols in Alzheimer’s disease
neuropathology. Nutr Diet Suppl. 2010;2010:97–103.
9. Wu CD. Grape products and oral health. J Nutr. 2009;139:1818S–23S.
10. Baumann LS. Less-known botanical cosmeceuticals. Dermatol Ther. 2007;20:
330–42.
11. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM,
Vargas E, Capella D, Bonfill Cosp X. Phlebotonics for venous insufficiency.
Cochrane Database Syst Rev. 2016;4:CD003229.
12. World Health Organization (WHO). Constitution of the World Health
Organization - basic documents, vol. Supplement. 45th ed. 2006.
13. Michaud JMJRAM. Synthèse des procyanidines naturelles. Ann Pharm Fr.
1973;31:385–95.
14. Dewick PM. The Shikimate Pathway: Aromatic Amino Acids and Phenylpropanoids.
In: Medicinal Natural Products. Hoboken: Wiley; 2009. p. 137–86.
15. Xie D-Y, Dixon RA. Proanthocyanidin biosynthesis – still more questions
than answers? Phytochemistry. 2005;66:2127–44.
16. He F, Pan QH, Shi Y, Duan CQ. Biosynthesis and genetic regulation of
proanthocyanidins in plants. Molecules. 2008;13:2674–703.
17. Dixon RA, Xie D-Y, Sharma SB. Proanthocyanidins – a final frontier in
flavonoid research? New Phytol. 2005;165:9–28.
18. Vaughn KC, Lax AR, Duke SO. Polyphenol oxidase: The chloroplast oxidase
with no established function. Physiol Plant. 1988;72:659–65.
19. Creasy LL, Swain T. Structure of condensed tannins. Nature. 1965;208:151–3.
20. Baxter IR, Young JC, Armstrong G, Foster N, Bogenschutz N, Cordova T, Peer
WA, Hazen SP, Murphy AS, Harper JF. A plasma membrane H+-ATPase is
required for the formation of proanthocyanidins in the seed coat
endothelium of Arabidopsis thaliana. Proc Natl Acad Sci U S A. 2005;102:
2649–54.
21. Hemingway RW, Foo LY, Porter LJ. Linkage isomerism in trimeric and
polymeric 2,3-cis-procyanidins. J Chem Soc, Perkin Trans. 1982;1:1209–16.
22. St Leger AS, Cochrane AL, Moore F. Factors associated with cardiac
mortality in developed countries with particular reference to the
consumption of wine. Lancet. 1979;1:1017–20.
23. Prior RL, Gu L. Occurrence and biological significance of proanthocyanidins
in the American diet. Phytochemistry. 2005;66:2264–80.




accessed. Accessed 30 June 2016.
25. Gu L, Kelm MA, Hammerstone JF, Beecher G, Holden J, Haytowitz D,
Gebhardt S, Prior RL. Concentrations of proanthocyanidins in common
foods and estimations of normal consumption. J Nutr. 2004;134:613–7.
26. Zamora-Ros R, Knaze V, Rothwell J, Hémon B, Moskal A, Overvad K,
Tjønneland A, Kyrø C, Fagherazzi G, Boutron-Ruault M-C, et al. Dietary
polyphenol intake in Europe: the European Prospective Investigation into
Cancer and Nutrition (EPIC) study. Eur J Nutr. 2015;55:1–17.
27. Vogiatzoglou A, Mulligan AA, Luben RN, Lentjes MAH, Heiss C, Kelm M,
Merx MW, Spencer JPE, Schroeter H, Kuhnle GGC. Assessment of the dietary
intake of total flavan-3-ols, monomeric flavan-3-ols, proanthocyanidins and
theaflavins in the European Union. Br J Nutr. 2014;111:1463–73.
28. Knaze V, Zamora-Ros R, Lujan-Barroso L, Romieu I, Scalbert A, Slimani N,
Riboli E, van Rossum CT, Bueno-de-Mesquita HB, Trichopoulou A, et al.
Intake estimation of total and individual flavan-3-ols, proanthocyanidins and
theaflavins, their food sources and determinants in the European
Prospective Investigation into Cancer and Nutrition (EPIC) study. Br J Nutr.
2012;108:1095–108.
29. Sebastian RS, Wilkinson Enns C, Goldman JD, Martin CL, Steinfeldt LC,
Murayi T, Moshfegh AJ. A New database facilitates characterization of
flavonoid intake, sources, and positive associations with diet quality among
US adults. J Nutr. 2015;145:1239–48.
30. Wang Y, Chung S-J, Song WO, Chun OK. Estimation of daily
proanthocyanidin intake and major food sources in the U.S. diet. J Nutr.
2011;141:447–52.
31. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and
isoflavone intakes. Nutr Cancer. 2006;55:1–12.
32. Chan SG, Ho SC, Kreiger N, Darlington G, Adlaf EM, So KF, Chong PY.
Validation of a food frequency questionnaire for assessing dietary soy
isoflavone intake among midlife Chinese women in Hong Kong. J Nutr.
2008;138:567–73.
33. Chan SG, Ho SC, Kreiger N, Darlington G, So KF, Chong PY. Dietary sources
and determinants of soy isoflavone intake among midlife Chinese Women
in Hong Kong. J Nutr. 2007;137:2451–5.
34. Kim J-S, Kwon C-S. Estimated dietary isoflavone intake of Korean population
based on National Nutrition Survey. Nutr Res. 2001;21:947–53.
35. Li G, Zhu Y, Zhang Y, Lang J, Chen Y, Ling W. Estimated daily flavonoid and
stilbene intake from fruits, vegetables, and nuts and associations with lipid
profiles in Chinese adults. J Acad Nutr Diet. 2013;113:786–94.
36. Woo H, Lee J, Choi I, Kim C, Lee J, Kwon O, Kim J. Dietary flavonoids and
gastric cancer risk in a Korean population. Nutrients. 2014;6:4961–73.
37. Otaki N, Kimira M, Katsumata S-i, Uehara M, Watanabe S, Suzuki K.
Distribution and major sources of flavonoid intakes in the middle-aged
Japanese women. J Clin Biochem Nutr. 2009;44:231–8.
38. Johannot L, Somerset SM. Age-related variations in flavonoid intake and
sources in the Australian population. Public Health Nutr. 2006;9:1045–54.
39. Ivey KL, Lewis JR, Lim WH, Lim EM, Hodgson JM, Prince RL. Associations of
proanthocyanidin intake with renal function and clinical outcomes in
elderly women. PLoS One. 2013;8:e71166.
40. Arabbi PR, Genovese MI, Lajolo FM. Flavonoids in vegetable foods
commonly consumed in brazil and estimated ingestion by the Brazilian
Population. J Agric Food Chem. 2004;52:1124–31.
41. Corrêa VG, Tureck C, Locateli G, Peralta RM, Koehnlein EA. Estimate of
consumption of phenolic compounds by Brazilian population. Rev Nutr.
2015;28:185–96.
42. Neveu V, Perez-Jiménez J, Vos F, Crespy V, du Chaffaut L, Mennen L, Knox C,
Eisner R, Cruz J, Wishart D, Scalbert A. Phenol-Explorer: an online
comprehensive database on polyphenol contents in foods. Database
(Oxford). 2010;2010:bap024.
43. World Health Organization (WHO). Diet, nutrition and the prevention of
chronic diseases In: WHO Tech Rep Ser, vol. No. 916 (TRS 916). Geneva:
WHO; 2003.
44. Bauer R. Quality criteria and standardization of phytopharmaceuticals: Can
acceptable drug standards be achieved? Drug Inf J. 1998;32:101–10.
45. Singleton VL, Rossi JA. Colorimetry of total phenolics with phosphomolybdic-
phosphotungstic acid reagents. Am J Enol Vitic. 1965;16:144–58.
46. Stalikas CD. Extraction, separation, and detection methods for phenolic
acids and flavonoids. J Sep Sci. 2007;30:3268–95.
47. Bate-Smith EC. Phytochemistry of proanthocyanidins. Phytochemistry. 1975;
14:1107–13.
48. Porter LJ, Hrstich LN, Chan BG. The conversion of procyanidins and
prodelphinidins to cyanidin and delphinidin. Phytochemistry. 1985;25:223–30.
49. Schofield P, Mbugua DM, Pell AN. Analysis of condensed tannins: a review.
Anim Feed Sci Technol. 2001;91:21–40.
50. Sun B, Ricardo-da-Silva JM, Spranger I. Critical factors of vanillin assay for
catechins and proanthocyanidins. J Agric Food Chem. 1998;46:4267–74.
51. Naczk M, Shahidi F. Phenolics in cereals, fruits and vegetables: occurrence,
extraction and analysis. J Pharm Biomed Anal. 2006;41:1523–42.
52. Ignat I, Volf I, Popa VI. A critical review of methods for characterisation of
polyphenolic compounds in fruits and vegetables. Food Chem. 2011;126:1821–35.
53. Khoddami A, Wilkes MA, Roberts TH. Techniques for analysis of plant
phenolic compounds. Molecules. 2013;18:2328–75.
54. Dumon M, Michaud J, Masquelier J. Dosages des procyanidols dans les
extraits végétaux destinés a la préparation de médicaments. Bull Soc Pharm
Bord. 1990;129:51–65.
55. Dumon M. Recherches analytiques sur les pycnogenols. PhD thesis. Bordeaux:
Université de Bordeaux II, UFR des Sciences Pharmaceutiques; 1990.
56. de Haan B, Achanta G, Post JA. A potential role for oligomeric
proanthocyanidins (OPCs) in delaying senescence in human endothelial
cells. Free Radic Biol Med. 2008;45:S78.
57. Krishnan P, Kruger NJ, Ratcliffe RG. Metabolite fingerprinting and profiling in
plants using NMR. J Exp Bot. 2005;56:255–65.
58. Hylands PJN, JK, Holmes E, Dunn MJ. Process for quality control and
standardization of medicinal plant products. In Google patent, vol.
US6806090 B1. USA; 2004.
59. Laparra J, Michaud J, Masquelier J. Étude pharmacocinétique des
oligomères flavanoliques. Plantes Medicinales Phytotherapie. 1977;9:133–42.
60. Laparra J, Michaud J, Lesca MF, Blanquet P, Masquelier J. Étude
pharmacocinetique des oligomeres procyanidoliques totaux du raisin.
Acta Ther. 1978;4:233–46.
Weseler and Bast Nutrition Journal  (2017) 16:5 Page 17 of 19
61. Jacobs H, Koek GH, Peters R, Moalin M, Tack J, van der Vijgh WJ,
Bast A, Haenen GR. Differences in pharmacological activities of the
antioxidant flavonoid monoHER in humans and mice are caused by
variations in its metabolic profile. Clin Pharmacol Ther. 2011;90:852–
9.
62. Benakis A, Schopfer C, Ritschard J. Disposition of 14C-labelled ENDOTELON
in humans. Eur J Drug Metab Pharmacokinet. 2008;33:37–43.
63. Choy YY, Jaggers GK, Oteiza PI, Waterhouse AL. Bioavailability of intact
proanthocyanidins in the rat colon after ingestion of grape seed extract. J
Agric Food Chem. 2013;61:121–7.
64. Prasain JK, Peng N, Dai Y, Moore R, Arabshahi A, Wilson L, Barnes S, Michael
Wyss J, Kim H, Watts RL. Liquid chromatography tandem mass spectrometry
identification of proanthocyanidins in rat plasma after oral administration of
grape seed extract. Phytomedicine. 2009;16:233–43.
65. Serra A, Macia A, Romero MP, Salvado MJ, Bustos M, Fernandez-Larrea J,
Motilva MJ. Determination of procyanidins and their metabolites in plasma
samples by improved liquid chromatography-tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1169–76.
66. Tsang C, Auger C, Mullen W, Bornet A, Rouanet JM, Crozier A, Teissedre PL.
The absorption, metabolism and excretion of flavan-3-ols and procyanidins
following the ingestion of a grape seed extract by rats. Br J Nutr. 2005;94:170–81.
67. Actis-Goretta L, Leveques A, Rein M, Teml A, Schafer C, Hofmann U, Li H,
Schwab M, Eichelbaum M, Williamson G. Intestinal absorption, metabolism,
and excretion of (-)-epicatechin in healthy humans assessed by using an
intestinal perfusion technique. Am J Clin Nutr. 2013;98:924–33.
68. Ottaviani JI, Momma TY, Kuhnle GK, Keen CL, Schroeter H. Structurally related
(−)-epicatechin metabolites in humans: Assessment using de novo chemically
synthesized authentic standards. Free Radic Biol Med. 2012;52:1403–12.
69. Holt RR, Lazarus SA, Sullards MC, Zhu QY, Schramm DD, Hammerstone JF,
Fraga CG, Schmitz HH, Keen CL. Procyanidin dimer B2 [epicatechin-(4β-8)-
epicatechin] in human plasma after the consumption of a flavanol-rich
cocoa. Am J Clin Nutr. 2002;76:798–804.
70. Sano A, Yamakoshi J, Tokutake S, Tobe K, Kubota Y, Kikuchi M. Procyanidin
B1 is detected in human serum after intake of proanthocyanidin-rich grape
seed extract. Biosci Biotechnol Biochem. 2003;67:1140–3.
71. Deprez S, Mila I, Huneau JF, Tome D, Scalbert A. Transport of
proanthocyanidin dimer, trimer, and polymer across monolayers of human
intestinal epithelial Caco-2 cells. Antioxid Redox Signal. 2001;3:957–67.
72. Rios LY, Gonthier M-P, Rémésy C, Mila I, Lapierre C, Lazarus SA, Williamson G,
Scalbert A. Chocolate intake increases urinary excretion of polyphenol-derived
phenolic acids in healthy human subjects. Am J Clin Nutr. 2003;77:912–8.
73. Appeldoorn MM, Vincken JP, Aura AM, Hollman PC, Gruppen H. Procyanidin
dimers are metabolized by human microbiota with 2-(3,4-
dihydroxyphenyl)acetic acid and 5-(3,4-dihydroxyphenyl)-gamma-valerolactone
as the major metabolites. J Agric Food Chem. 2009;57:1084–92.
74. Stoupi S, Williamson G, Drynan JW, Barron D, Clifford MN. Procyanidin B2
catabolism by human fecal microflora: Partial characterization of ‘dimeric’
intermediates. Arch Biochem Biophys. 2010;501:73–8.
75. Wiese S, Esatbeyoglu T, Winterhalter P, Kruse H-P, Winkler S, Bub A, Kulling SE.
Comparative biokinetics and metabolism of pure monomeric, dimeric, and
polymeric flavan-3-ols: A randomized cross-over study in humans.
Mol Nutr Food Res. 2015;59:610–21.
76. Nakamura Y, Tsuji S, Tonogai Y. Analysis of proanthocyanidins in grape seed
extracts, health foods and grape seed oils. J Health Sci. 2003;49:45–54.
77. Masquelier J, Dumon M, Dumas J. Stabilisation du collagene par les
oligomeres procyanidoliques. Acta Ther. 1981;7:101–5.
78. Pfister A, Simon M, Gazave J. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon de
cobaye. Acta Ther. 1982;8:223–37.
79. Tixier JM, Godeau G, Robert AM, Hornebeck W. Evidence by in vivo and in
vitro studies that binding of pycnogenols to elastin affects its rate of
degradation by elastases. Biochem Pharmacol. 1984;33:3933–9.
80. Gavignet-Jeannin C, Groult N, Godeau G, Robert A, Robert L. Mode d’action
des oligomeres procyanidoliques sur la paroi vasculaire. Toulouse: Congrès
International d’Angiologie, symposium satellite Endotelon et unite
circulatoire; 1988.
81. Robert AM. Substrate-protecting antiproteolytic agents for the prevention of
pathological degradation of connective tissues. A review. Pathol Biol (Paris).
2012;60:48–57.
82. Oligomeric proanthocyanidins (OPCs). Monograph Altern Med Rev 2003,
8:442-450.
83. Bast A, Haenen GRMM. Ten misconceptions about antioxidants. Trends
Pharmacol Sci. 2013;34:430–6.
84. Weseler AR, Bast A. Oxidative stress and vascular function: implications for
pharmacologic treatments. Curr Hypertens Rep. 2010;12:154–61.
85. Masquelier J. Action comparee de divers facteurs vitaminiques P sur
l’oxydation de l’acide ascorbique par les ions cuivriques. Bull Soc Chim Biol
(Paris). 1951;33:302–5.
86. Masquelier J. Plant extract with a proanthocyanidins content as therapeutic
agent having radical scavenger effect and use thereof, vol. US4698360 A.
USA; 1987.
87. van Acker SA, de Groot MJ, van den Berg DJ, Tromp MN, Donne-Op den
Kelder G, van der Vijgh WJ, Bast A. A quantum chemical explanation of the
antioxidant activity of flavonoids. Chem Res Toxicol. 1996;9:1305–12.
88. Barbier AM, JP, Savi P, Unkovic J, Vilain P. Activité angioprotectrice des
oligomères procyanidoliques chez l’animal. Toulouse: Congrès International
d’Angiologie; 1988.
89. Meunier M, Duroux E, Bastide P. Activite antiradicalaire d’oligomeres
procyanidolique et d’anthocyanosides vis-a-vis de l’anion superoxyde et vis-a-
vis de la lipoperoxydation. Plantes Medicinales Phytotherapie. 1989;13:267–74.
90. Masquelier J. Effets physiologiques du vin - Sa part dans l’alcoolisme.
Bulletin de l’OIV. 1988;689:555–78.
91. de Haan B, Babat S, Post JA. Protection of vascular endothelial cells from
oxidative damage by oligomeric proanthocyanidins. In: Oxidants and
antioxidants in biology. Santa Barbara: Oxygen Club of California; 2006.
92. de Haan B, Babat S, Post JA. Oligomeric proanthocyanidins protect vascular
endothelial cells from lipid oxidation. Inflamm Res. 2006;Supplement 2:S116.
93. Bos MA, Vennat B, Meunier MT, Pouget MP, Pourrat A, Fialip J. Procyanidins
from tormentil: antioxidant properties towards lipoperoxidation and anti-
elastase activity. Biol Pharm Bull. 1996;19:146–8.
94. Ruijters EJ, Weseler AR, Kicken C, Haenen GR, Bast A. The flavanol
(-)-epicatechin and its metabolites protect against oxidative stress in
primary endothelial cells via a direct antioxidant effect. Eur J Pharmacol.
2013;715:147–53.
95. Granado-Serrano AB, Martin MA, Haegeman G, Goya L, Bravo L, Ramos S.
Epicatechin induces NF-kappaB, activator protein-1 (AP-1) and nuclear
transcription factor erythroid 2p45-related factor-2 (Nrf2) via
phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) and extracellular
regulated kinase (ERK) signalling in HepG2 cells. Br J Nutr. 2010;103:168–79.
96. Rodriguez-Ramiro I, Ramos S, Bravo L, Goya L, Martin MA. Procyanidin B2
induces Nrf2 translocation and glutathione S-transferase P1 expression via
ERKs and p38-MAPK pathways and protect human colonic cells against
oxidative stress. Eur J Nutr. 2012;51:881–92.
97. Ohnuma T, Anzai E, Suzuki Y, Shimoda M, Saito S, Nishiyama T, Ogura K,
Hiratsuka A. Selective antagonization of activated Nrf2 and inhibition of
cancer cell proliferation by procyanidins from Cinnamomi Cortex extract.
Arch Biochem Biophys. 2015;585:17–24.
98. Krajka-Kuzniak V, Paluszczak J, Oszmianski J, Baer-Dubowska W. Hawthorn
(Crataegus oxyacantha L.) bark extract regulates antioxidant response
element (ARE)-mediated enzyme expression via Nrf2 pathway activation in
normal hepatocyte cell line. Phytother Res. 2014;28:593–602.
99. Bak MJ, Jun M, Jeong WS. Procyanidins from wild grape (Vitis amurensis)
seeds regulate ARE-mediated enzyme expression via Nrf2 coupled with p38
and PI3K/Akt pathway in HepG2 cells. Int J Mol Sci. 2012;13:801–18.
100. Nazimabashir, Manoharan V, Miltonprabu S. Cadmium induced cardiac
oxidative stress in rats and its attenuation by GSP through the activation of
Nrf2 signaling pathway. Chem Biol Interact. 2015;242:179–93.
101. Chen S, Zhu Y, Liu Z, Gao Z, Li B, Zhang D, Zhang Z, Jiang X, Liu Z, Meng L,
et al. Grape seed proanthocyanidin extract ameliorates diabetic bladder
dysfunction via the activation of the Nrf2 pathway. PLoS One. 2015;10:
e0126457.
102. Blazso G, Gabor M. Oedema-inhibiting effect of procyanidin. Acta Physiol
Acad Sci Hung. 1980;56:235–40.
103. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev
Immunol. 2002;2:725–34.
104. Milenkovic D, Vanden Berghe W, Boby C, Leroux C, Declerck K, Szarc vel Szic
K, Heyninck K, Laukens K, Bizet M, Defrance M, et al. Dietary flavanols
modulate the transcription of genes associated with cardiovascular
pathology without changes in their DNA methylation state. PLoS One.
2014;9:e95527.
105. Ruijters EJ, Haenen GR, Weseler AR, Bast A. The cocoa flavanol
(-)-epicatechin protects the cortisol response. Pharmacol Res. 2014;79:28–33.
Weseler and Bast Nutrition Journal  (2017) 16:5 Page 18 of 19
106. Ruijters EJ, Haenen GR, Willemsen M, Weseler AR, Bast A. Food-derived
bioactives can protect the anti-inflammatory activity of cortisol with
antioxidant-dependent and -independent mechanisms. Int J Mol Sci.
2016;17:239–48.
107. Weseler AR, Bast A. Pleiotropic-acting nutrients require integrative
investigational approaches: the example of flavonoids. J Agric Food Chem.
2012;60:8941–6.
108. Dartenuc J, Marache P, Choussat H. Resistance capillaire en geriatrie: etude
d’un microangioprotecteur endotelon. Bordeaux Med. 1980;13:903–7.
109. Dubos G, Durst G, Hugonot R. Evolution de la resistance capillaire,
spontanement ou artificiellement diminuee par l’action d’un substance
capillaro-toxique chez des personnes agees. Revue Geriatr. 1980;5:302–5.
110. Paitel D. Etude rheographique et thermographic des effets d’un
endotheliotrophique sur l’hemodynamique peripherique. Vie Med.
1981;11:776–83.
111. Beylot C, Bioulac P. Essai therapeutique d’un angioprotecteur peripherique,
l’Endotelon. Gaz Med (Paris). 1980;87:2919–22.
112. Elbaz C, Reinharez D, Sapin G, Brami C, Boschet P, Gounon P, Roure M,
Tragit R, Vergoz L. Etude multicentrique controlee de l’endotelon dans les
manifestations fonctionelles de l’insufficance veineuse chronique des
membres inferieurs. Le Praticien. 1981;400:63–8.
113. Thebaut J-F, Thebaut P, Vin F. Etude de l’endotelon dans les manifestations
functionelles de l’insufficisance veineuse peripherique. Resultats d’une etude
en double aveugle portant sur 92 patients. Gaz Med (Paris). 1985;92:96–100.
114. Weseler AR, Ruijters EJ, Drittij-Reijnders MJ, Reesink KD, Haenen GR, Bast A.
Pleiotropic benefit of monomeric and oligomeric flavanols on vascular health -
a randomized controlled clinical pilot study. PLoS One. 2011;6:e28460.
115. Aragones G, Suarez M, Ardid-Ruiz A, Vinaixa M, Rodriguez MA, Correig X,
Arola L, Blade C. Dietary proanthocyanidins boost hepatic NAD(+)
metabolism and SIRT1 expression and activity in a dose-dependent manner
in healthy rats. Sci Rep. 2016;6:24977.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Weseler and Bast Nutrition Journal  (2017) 16:5 Page 19 of 19
